Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Down 1.4%

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report)'s share price fell 1.4% during mid-day trading on Friday . The stock traded as low as $112.74 and last traded at $113.00. 72,943 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 668,404 shares. The stock had previously closed at $114.55.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JAZZ. Barclays decreased their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating on the stock in a report on Friday, May 3rd. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a report on Monday. Wells Fargo & Company reduced their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating on the stock in a report on Thursday, August 1st. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a "buy" rating and a $169.00 target price on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $173.07.

Jazz Pharmaceuticals Stock Performance

The company has a market cap of $7.18 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58. The stock has a 50-day moving average price of $109.11 and a 200 day moving average price of $113.14. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Rise Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 203 shares during the period. Versant Capital Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after purchasing an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.